Paralytic lagophthalmos

Summary

Paralytic lagophthalmos (MONDO:0001603) is a disease and 4 clinical trials. A subtype of lagophthalmos — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	paralytic lagophthalmos
Mondo ID	MONDO:0001603
DOID	DOID:12958
ICD-10-CM	H02.23
ICD-11	2122617367
UMLS	C0155197
MedGen	509844
Is cancer (heuristic)	no

Also known as: paralytic lagophthalmos · paralytic lagophthalmos (disease)

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of lagophthalmos. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye adnexa disorder › eyelid disorder › lagophthalmos › paralytic lagophthalmos

Related subtypes (2): mechanical lagophthalmos, cicatricial lagophthalmos

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06895902	EARLY_PHASE1	RECRUITING	Suture Lid Spring for Lid Closure in Patients With Facial Nerve Palsy
NCT06291818	Not specified	RECRUITING	Self-Adhering Magnetic Device to Treat Corneal Exposure
NCT03848260	Not specified	SUSPENDED	A Real-Time Magnetic Device Prototype for Temporary Management of Paralytic Lagophthalmos
NCT04944498	Not specified	COMPLETED	Modified Tarsorrhaphy vs Gold Weight Implant for Paralytic Lagophthalmos in Leprosy Patients